RESUMEN

Standards for talking and thinking about validity have been promulgated in North America for decades. In 1954 two foundational standards were announced: (a) Thou shalt not refer to "the validity of the test" and (b) thou shalt use validity modifier labels, such as "content validity" or "predictive validity." Subsequently, in 1985, the latter became, thou shalt not use validity modifier labels. These standards for talking about validity have repeatedly been disregarded over the years. Possible reasons include intentional misuse, while upholding standards for thinking about validity; lack of awareness or misunderstanding of standards for thinking about validity; and genuine divergence from standards for thinking about validity. A historical analysis of disregard for these standards provides a basis for reappraising the concept of validity. We amassed a new body of evidence with which to challenge the frequently asserted claim that a general consensus exists over the meaning of validity. Indeed, the historical analysis provides reason to believe that prospects for achieving consensus over the meaning of validity are low. We recommend that the concept of validity be abandoned in favor of the more general, all-encompassing concept of quality, to be judged in relation to measurement aims, decision making aims, and broader policy aims, respectively.

Asunto(s)

RESUMEN

EXPAREL (bupivacaine extended-release liposome injection), DepoFoam bupivacaine, is in development for prolonged postsurgical analgesia. Repeat-dose toxicity studies were conducted in rabbits and dogs to compare the potential local and systemic toxicities of EXPAREL and bupivacaine HCl (Bsol), and the reversibility of any effects. Dogs tolerated much larger doses than rabbits. EXPAREL-related minimal-to-moderate granulomatous inflammation was noted at the injection sites. In recovery animals, the granulomatous inflammation was observed less frequently and was characterized by an increased number of multinucleated giant cells. These effects were considered a normal response to liposomes and nonadverse. Rabbits are more sensitive than dogs. In rabbits, convulsions were noted with EXPAREL and more frequently with Bsol; a NOAEL was not identified. In dogs, EXPAREL was well tolerated (NOAEL > 30 mg/kg/dose). The cumulative exposure of EXPAREL in these studies is well in excess of the proposed maximum single-dose exposure that is intended in humans.

RESUMEN

OBJECTIVE: DepoFoam bupivacaine (DB) is in development for prolonged postoperative analgesia. Studies were conducted to evaluate the potential local and systemic toxicity and any effect on wound healing after wound infiltration. METHODS: The model simulates an inguinal hernia (skin incision ∼2.5 and 5.5 cm). Animals (four/sex/group of each species) received DB 9, 18 or either 25 or 30 mg/kg, bupivacaine solution (B(sol); 7.5 mg/ml, 9 mg/kg) or saline. DB was given at 0.6, 1.2 and 1.0 or 1.2 ml/kg, respectively, and B(sol) or saline at 1.2 ml/kg. Each dose was infiltrated in small fractions on Day 1. End points included histology on Days 3 and 15. Wound healing was recorded on Day 2 through Day 15. RESULTS: There was no adverse effect in either species. Notably, granulomatous inflammation was noted in surgical sites from 8 of 24 rabbits in the DB groups only. Based on the minimal to mild severity on Day 15, this was considered a normal reaction against the liposomes. Except for granulomatous inflammation, there were no differences in overall incidence or severity of histologic changes in the sites dosed to DB, saline or B(sol). CONCLUSIONS: The data reported here are the first demonstration of the safety of DB in toxicology species.

Asunto(s)

RESUMEN

Asphalt (bitumen) fume condensates collected from the headspace above paving and Type III built up roofing asphalt (BURA) tanks were evaluated in two-year dermal carcinogenicity assays in male C3H/HeNCrl mice. A third sample was generated from the BURA using a NIOSH laboratory generation method. Similar to earlier NIOSH studies, the BURA fume condensates were applied dermally in mineral oil twice per week; the paving sample was applied 7 days/week for a total weekly dose of 50 mg/wk in both studies. A single benign papilloma was observed in a group of 80 mice exposed to paving fume condensate at the end of the two-year study and only mild skin irritation was observed. The lab generated BURA fume condensate resulted in statistically significant (P<0.0001) increases in squamous cell carcinomas (35 animals or 55% of animals at risk). The field-matched BURA condensate showed a weaker but significant (P=0.0063) increase (8 carcinomas or 13% of animals) and a longer average latency (90 weeks vs. 76 for the lab fume). Significant irritation was observed in both BURA condensates. It is concluded that the paving fume condensate was not carcinogenic under the test conditions and that the field-matched BURA fume condensate produced a weak tumor response compared to the lab generated sample.

Asunto(s)

RESUMEN

BACKGROUND/AIMS: GBR12909 has been reported to possess anticonvulsant activity with focal brain perfusion to the hippocampus of pilocarpine, although an earlier publication suggested any anticonvulsant effects were only mild. Here we further explored the anticonvulsant potential of GBR12909 with a suite of anticonvulsant assays in both zebrafish and mammals and then explored whether it possessed any QT effects which might limit clinical utility. METHODS: We assessed the anticonvulsant effects of GBR12909 in zebrafish pentylenetetrazole (PTZ), mammalian maximal electroshock and PTZ models of generalized epilepsy and a rodent hippocampal kindling model. Cardiac effects were assessed in zebrafish and man. RESULTS: GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy. However, phase 1 human data indicated potential QT effects. Subsequent testing in a zebrafish QT assay confirmed marked arrhythmogenic potential. CONCLUSION: Further clinical development of GBR12909 in epilepsy was considered inappropriate because of insufficient window between the therapeutic effects and the cardiac arrhythmia problems identified in zebrafish assays. Any further development based on this mechanism of action should avoid the GBR12909 chemical scaffold, or involve structure-activity dissociation of its neurological and cardiac effects.

Asunto(s)

RESUMEN

Methylethylketoxime, also known as MEKO or 2-butanone oxime (CAS No. 96-29-7), is a clear, colorless to light yellow liquid at room temperature. It is an industrial antioxidant used as an antiskinning agent in alkyd paint, an industrial blocking agent for urethane polymers, and a corrosion inhibitor in industrial boilers, and can be found in some adhesives and silicone caulking products. Male CD-1 mice were exposed 6 h/day, 5 days/wk, for 1, 2, 4, or 13 wk via whole-body inhalation exposures to MEKO vapor concentrations of 0, 3 +/- 0.1, 10 +/- 0.3, 30 +/- 1, or 100 +/- 2 ppm (10 mice/group/interval). Satellite animals were removed after 1, 2, 4, or 13 wk of exposure and allowed to recover for 4 or 13 wk (5 mice/group/interval). After termination, the nasal turbinates were evaluated microscopically, and cross-sectional nasal maps of the lesions were prepared. At the end of the 1-, 2-, 4-, and 13-wk exposure periods, degeneration of the olfactory epithelium lining the dorsal meatus was seen in the anterior region of the nasal cavity. In a few instances, the olfactory epithelium covering the tips of the nasoturbinal scrolls projecting into the dorsal region of the nasal cavity was also degenerated. Large areas of olfactory epithelium lying laterally and posteriorly were unaffected. In general, approximately 10% or less of the total olfactory tissue was affected. In several instances, the degenerated olfactory epithelium was reepithelialized by squamous/squamoid and/or respiratory types of epithelium. Degeneration, which was dose related in incidence and severity, was seen in mice exposed to 30 and 100 ppm after 1 wk of exposure and in several mice exposed to 10 ppm after 13 wk of exposure. The incidence and severity of the degeneration present after 1 wk of exposure did not increase with the longer exposures. The olfactory degeneration was reversible. Recovery was complete within 4 wk following exposures at 10 ppm and nearly complete within 13 wk after exposures at 30 and 100 ppm. A no-observed-effect level (NOEL) for the olfactory degeneration was considered to be 3 ppm.

Asunto(s)